Warma Neil K 4

What Happened

• Neil K. Warma, CEO of ProMIS Neurosciences (PMN), received a derivative award on 2026-05-20 covering 160,000 shares (reported acquisition price $0.00). The Form 4 classifies the grant as an award/derivative (A) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-20; reported acquisition price: $0.00; quantity: 160,000 (derivative interest).
• Filing date: 2026-05-22 (filed within the typical two-business-day Form 4 window).
• Footnote: the shares subject to this option vest ratably over four years, contingent on continued service to the company.
• Shares owned after the transaction: not specified in the provided summary.
• Transaction type: award/option grant (not an immediate cash purchase or sale).

Context

• This was an option/award grant, meaning Warma did not purchase shares on the open market; the economic benefit depends on vesting and any future exercise terms. Such awards are common for executive compensation and do not by themselves indicate an immediate trading signal.